Wave Life Sciences (WVE) Price & Analysis

Compare

969 Followers

WVE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.28 - $16.74

Previous CloseN/A

Volume104.35K

Average Volume (3M)2.39M

Market Cap

$1.21B

Enterprise Value$887.02M

Total Cash (Recent Filing)$208.48M

Total Debt (Recent Filing)$21.71M

Price to Earnings (P/E)―

Beta1.82

Next Earnings

Nov 06, 2025

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.31

Shares Outstanding159,140,460

10 Day Avg. Volume2,406,848

30 Day Avg. Volume2,387,777

Financial Highlights & Ratios

PEG Ratio-0.60

Price to Book (P/B)8.16

Price to Sales (P/S)15.79

P/FCF Ratio-11.26

Enterprise Value/Market Cap0.73

Enterprise Value/Revenue9.44

Enterprise Value/Gross Profit9.90

Enterprise Value/Ebitda-6.58

Forecast

1Y Price Target

$18.92

Price Target Upside148.95% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Analyst RecommendationAnalyst recommends buying WVE stock with a target price of $19.

Clinical Trial DataWVE-006 can protect patients when they need it, even after a single dose.

Bears Say

Competitive LandscapeThe competitive landscape has not evolved significantly, making it too early to call a winner or loser.

Stock PerformanceDespite the encouraging data, Wave's stock is down by nearly 20%, which is seen as an overreaction to unjustified threshold value ascribed for total AAT and M AAT levels.

Wave Life Sciences News

Invivyd appoints Wave Life Sciences CEO Paul Bolno to board

Invivyd (IVVD) announced the appointment of Paul Bolno to its board of directors and as a member of...

19d ago

WVE

IVVD

Wave Life Sciences Receives Buy Rating Amid Promising AATD Treatment Developments and Strategic Positioning

Whitney Ijem, an analyst from Canaccord Genuity, maintained the Buy rating on Wave Life Sciences. The associated price...

17d ago

WVE

Wave Life Sciences Highlights WVE-007 Obesity Treatment

The latest update is out from Wave Life Sciences ( ($WVE) ). On September 24, 2025, Wave Life...

18d ago

WVE

B. Riley ‘aggressive’ buyer of Wave Life on ‘material disconnect’

B. Riley reiterates a Buy rating on Wave Life Sciences (WVE) with a $19 price target after the...

1M ago

WVE

Wave Life Sciences: Strong Buy Rating Backed by Promising WVE-006 Trial Results and Strategic GSK Partnership

Wave Life Sciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Whitney Ijem...

1M ago

WVE

Wave Life Sciences price target lowered to $18 from $21 at Wells Fargo

Wells Fargo analyst Tiago Fauth lowered the firm’s price target on Wave Life Sciences (WVE) to $18 from...

1M ago

WVE

Why Is Wave Life Sciences Stock (WVE) Down 20% Today?

Wave Life Sciences stock fell hard on Wednesday alongside a clinical trial update. ...

1M ago

GSK

WVE

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Earnings reports, awards, collaborations, and more make up the biggest stock market stories for Wednesday. ...

1M ago

CRM

Optimistic Buy Rating for Wave Life Sciences Driven by Promising RNA Editing Technology and Strong Safety Profile

Wave Life Sciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong...

1M ago

WVE

Wave Life Sciences price target raised to $26 from $24 at Leerink

Leerink raised the firm’s price target on Wave Life Sciences (WVE) to $26 from $24 and keeps an...

1M ago

WVE

Beam competitive position intact after Wave data, says Clear Street

Clear Street says Beam Therapeutics (BEAM) is rallying after Wave Life Sciences (WVE) reported a data update from...

1M ago

WVE

BEAM

Promising Prospects for Wave Life Sciences: Fein’s Buy Rating Backed by WVE-006 Data and Strategic Partnerships

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Wave Life Sciences. The associated price...

1M ago

WVE

Wave Life Sciences pullback an ‘overreaction,’ says H.C. Wainwright

H.C. Wainwright analyst Andrew Fein says WVE-006’s latest dataset confirms “robust,” dose-dependent increases in functional M-AAT alongside meaningful...

1M ago

WVE

Alphabet jumps after avoiding worst case in antitrust ruling: Morning Buzz

The S&P and Nasdaq indexes have received a lift from a landmark court ruling in Alphabet’s (GOOGL) favor....

1M ago

WVE FAQ

What was Wave Life Sciences’s price range in the past 12 months?

Wave Life Sciences lowest stock price was $5.28 and its highest was $16.73 in the past 12 months.

What is Wave Life Sciences’s market cap?

Wave Life Sciences’s market cap is $1.21B.

When is Wave Life Sciences’s upcoming earnings report date?

Wave Life Sciences’s upcoming earnings report date is Nov 06, 2025 which is in 24 days.

How were Wave Life Sciences’s earnings last quarter?

Wave Life Sciences released its earnings results on Jul 30, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.277 by -$0.033.

Is Wave Life Sciences overvalued?

According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Wave Life Sciences pay dividends?

Wave Life Sciences does not currently pay dividends.

What is Wave Life Sciences’s EPS estimate?

Wave Life Sciences’s EPS estimate is -0.26.

How many shares outstanding does Wave Life Sciences have?

Wave Life Sciences has 159,140,460 shares outstanding.

What happened to Wave Life Sciences’s price movement after its last earnings report?

Wave Life Sciences reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.277. Following the earnings report the stock price went down -1.923%.

Which hedge fund is a major shareholder of Wave Life Sciences?

Currently, no hedge funds are holding shares in WVE

Wave Life Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-171.41%

Trailing 12-Months

Asset Growth

20.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company focused on developing transformative medicines for patients with genetic diseases. The company specializes in precision medicine and leverages its proprietary technologies to design and develop oligonucleotide therapies targeting genetic disorders. Wave's core products include a pipeline of drug candidates aimed at treating various neurological and rare diseases, utilizing their innovative curvature technology to enhance therapeutic efficacy.

Wave Life Sciences (WVE) Earnings & Revenues

Historic Earnings Reports

WVE Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflected significant progress in clinical programs, particularly in INHBE for obesity and AATD. However, financial performance showed challenges with decreased revenue and increased net loss. The sentiment is balanced with both positive clinical updates and financial challenges.View all WVE earnings summaries

WVE Stock 12 Month Forecast

Average Price Target

$18.92

▲(148.95% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","16":"$16","27":"$27","10.5":"$10.5","21.5":"$21.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10.5,16,21.5,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.03,8.489230769230769,9.948461538461538,11.407692307692308,12.866923076923076,14.326153846153847,15.785384615384615,17.244615384615383,18.703846153846154,20.163076923076922,21.622307692307693,23.08153846153846,24.54076923076923,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.03,7.944615384615385,8.85923076923077,9.773846153846154,10.688461538461539,11.603076923076923,12.517692307692307,13.432307692307692,14.346923076923076,15.26153846153846,16.176153846153845,17.09076923076923,18.005384615384617,{"y":18.92,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.03,7.181538461538461,7.3330769230769235,7.484615384615385,7.636153846153846,7.787692307692308,7.939230769230769,8.090769230769231,8.242307692307692,8.393846153846154,8.545384615384615,8.696923076923078,8.848461538461539,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.83,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >